We evaluated the potential of these 177Lu-labeled ligands as GRPR-targeted therapeutic agents by SPECT imaging and ex vivo biodistribution studies in GRPR-expressing tumor-bearing mice and dosimetry calculation. This evidence concerns the gene GRPR and neoplasm.